impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

One year in review

 

Seronegative rheumatoid arthritis: one year in review 2023

1, 2, 3, 4, 5, 6, 7, 8

 

  1. Department of Internal Medicine and Therapeutics, Università di Pavia, and Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  2. Department of Internal Medicine and Therapeutics, Università di Pavia, and Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  3. U.O. di Reumatologia, Ospedale San Giovanni Bosco, Napoli, Italy.
  4. Department of Internal Medicine and Therapeutics, Università di Pavia, and Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  5. Dipartimento di Medicina di Precisione, Università della Campania L. Vanvitelli, Napoli, Italy.
  6. Department of Internal Medicine and Therapeutics, Università di Pavia, and Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  7. Dipartimento di Medicina di Precisione, Università della Campania L. Vanvitelli, Napoli, Italy.
  8. Department of Internal Medicine and Therapeutics, Università di Pavia, and Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. serena.bugatti@unipv.it

CER16652
2023 Vol.41, N°3
PI 0554, PF 0564
One year in review

Free to view
(click on article PDF icon to read the article)

PMID: 36971084 [PubMed]

Received: 07/03/2023
Accepted : 13/03/2023
In Press: 23/03/2023
Published: 23/03/2023

Abstract

In the past 20 years, earlier diagnosis and more intensive management have considerably improved the prognosis of rheumatoid arthritis (RA), with milder disease course achieved in particular in seropositive patients. In contrast, seronegative RA has remained largely neglected, and continues to be surrounded by uncertainties regarding its correct diagnosis, clinical phenotype, optimal treatment strategies and relevant outcomes. The purpose of this review is to summarise new insights about the pathogenic, clinical and prognostic peculiarities of seronegative RA that emerged during 2022, and that make this disease subset at least partially different from its seropositive counterpart.

DOI: https://doi.org/10.55563/clinexprheumatol/go7g26

Rheumatology Article